Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 13/20 | 0.34 |
| ▸ | SRC | P12931 | 13/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302029 | 0.89 | KDM4E (0.40) | KDM4EHTTSRCPARP1 | |
| SCHEMBL30353910 | 0.87 | BRD4 (0.41) | KDM4EHTTSRCPARP1 | |
| SCHEMBL15328198 | 0.87 | BRD4 (0.41) | KDM4EHTTSRCPARP1 | |
| SCHEMBL23068614 | 0.86 | PARP1 (0.39) | KDM4ESYKSRCPARP1 | |
| SCHEMBL3177805 | 0.83 | KDM4E (0.37) | KDM4EHTTSRCPARP1 | |
| SCHEMBL3203162 | 0.80 | SRC (0.43) | KDM4EKDRSRC | |
| SCHEMBL3198358 | 0.80 | IP6K1 (0.54) | PARP1 | |
| SCHEMBL6826990 | 0.80 | SRC (0.52) | SYKKDRSRC | |
| SCHEMBL3183834 | 0.79 | KDM4E (0.37) | KDM4EHTTSYKKDRSRC | |
| SCHEMBL3193429 | 0.79 | QPCT (0.39) | KDM4EKDRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1463506-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | Astrazeneca AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | KDM4E 1346/4885HTT 4104/4885NPSR1 4066/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | KDM4E 1249/4885HTT 4587/4885NPSR1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.